- Advantages of the drug
Maximum activity already in the first 24 hours after administration3.
Enhances the production of antibodies and all types of interferons (alpha, beta, gamma, lambda).
Interferon lambda acts at the “entry gate” of the infection – the respiratory system, promoting its antiviral protection4.
Active at all stages of influenza and other acute respiratory viral infections: at the beginning, in the midst and during a protracted course. - Conducted studies
Amiksin has been clinically studied. More than 400 research papers have been published, in which the antiviral effect of the active substance of the drug – tilorone – has been experimentally and clinically confirmed5. Almost two dozen clinical trials and more than 39 thousand patient participants6. - Advantages of the release form
In case of influenza and other acute respiratory viral infections, it helps to reduce – the duration of fever by 1.5 times – symptoms of intoxication by 1.4 times – the risk of complications by 2.4 times6.
A preventive course of taking Amiksin during the seasonal rise in colds helps reduce the incidence of ARVI by up to 3.4 times6.
A convenient regimen for treating influenza and other ARVI: 1 tablet per day – on the 1st, 2nd, 4th, 6th, 8th, 10th day for adults 18+. Only 6 tablets per course.
